Terms ending in 2035
Every in-force patent on Ucb Pharma S.A.'s record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,789,254 | Auto-Injector In force · High confidence | Ucb Biopharma SPRL | In force | High confidence | |
| US 9,821,123 | Auto-Injector In force · High confidence | Ucb Biopharma SPRL | In force | High confidence | |
| US 11,426,359 | Method for Adjusting the Release of Active Agent in a Transdermal Delivery System In force · High confidence | LTS Lohmann Therapie-Systeme AG | In force | High confidence | |
| US 10,342,925 | Auto-Injector In force · Medium confidence | Ucb Biopharma SPRL | In force | Medium confidence | |
| US 10,975,066 | Bis-Heteroaryl Derivatives as Modulators of Protein Aggregation In force · Medium confidence | Ucb Biopharma SRL | In force | Medium confidence | |
| US 10,202,405 | Fused Pentacyclic Imidazole Derivatives In force · High confidence | Ucb Biopharma SRL | In force | High confidence | |
| US 10,906,919 | Fused Pentacyclic Imidazole Derivatives In force · High confidence | Ucb Biopharma SRL | In force | High confidence | |
| US 10,705,094 | TNF Receptor Signaling Modulator Assay In force · High confidence | Ucb Biopharma SRL | In force | High confidence | |
| US 10,883,996 | Methods of identifying signaling modulators of the trimeric TNFa In force · High confidence | Ucb Biopharma SRL | In force | High confidence | |
| US 10,969,393 | Complexes between anti-TNF antibodies, trimeric TNF proteins and organic molecules binding them In force · High confidence | Ucb Biopharma SRL | In force | High confidence | |
| 3 more term ends in 2035 · Pro | |||||
10 of 13 patents shown. Soonest term end first, then patent number.
Pro members see all 13.
1 of these is in force and held by Ucb Pharma S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.